KRAS and colorectal cancer: The potential for statins to synergize with established chemotherapeutic agents is also noteworthy; Tsubaki et al. demonstrated that simvastatin enhances the antitumour effect of oxaliplatin in KRAS mutated colorectal cancer cells while potentially reducing oxaliplatin-induced peripheral neuropathy [61].